This proposal is for a K08 Award for Dr. Duyen Dang. Dr. Dang graduated from Harvard Medical school in 1994. Thereafter, she trained clinically in Internal Medicine and Gastroenterology. She has dedicated the past two years to scientific training in Dr. Vincent Yang's laboratory at Johns Hopkins University School of Medicine. The focus of her studies has been the role of the gut-enriched Kruppel-like factor (GKLF), a potent inhibitor of epithelial cell growth, in intestinal tumorigenesis. The mammalian gut epithelium is a dynamic system in which cell proliferation is coupled to differentiation. Aberrations in this process lead to disease states such as colon cancer. Mutations of the tumor suppressor gene Adenomatous Polyposis Coli (APC) have been shown to initiate neoplastic transformation in most colorectal cancers. This application proposes to establish two transcription factors, CDX2 and GKLF as downstream mediators of the APC pathway. The hypotheses are: (1) APC regulates CDX2 expression, (2) CDX2 regulates GKLF expression, enterocyte differentiation, and cell growth; while dominant negative mutations of CDX2 inhibit this regulation, and (3) over-expression of GKLF leads to reduced malignancy.
Three specific aims are proposed to test these hypotheses:
Specific Aim 1 : To evaluate whether APC regulates CDX2 expression at the transcriptional or post-transcriptional level;
Specific Aim 2 : To evaluate a mutant CDX2 for dominant negative effects on the GKLF promoter, enterocyte differentiation, and growth suppression;
and Specific Aim 3 : To evaluate the impact of GKLF on the pathophysiology of colon cancer by assessing for GKLF mutations and evaluating the effect of GKLF over-expression on malignancy. The proposed research will contribute to the understanding of the mechanisms underlying intestinal development and colorectal tumorigenesis. In addition, the continued mentorship of Dr. Yang and the didactic and methodology curriculum intrinsic to this proposal will provide Dr. Dang with a framework to learn the methods, theories, and concepts recess to embark on an independent research career.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK059970-05
Application #
6922889
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
2001-08-15
Project End
2006-07-31
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
5
Fiscal Year
2005
Total Cost
$131,490
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Chun, S Y; Chen, F; Washburn, J G et al. (2007) CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3. Oncogene 26:4725-9
Dang, Duyen T; Chen, Fang; Gardner, Lawrence B et al. (2006) Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 66:1684-936
Dang, L H; Chen, F; Knock, S A et al. (2006) CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45. Oncogene 25:2048-59
Dang, Duyen T; Chen, Fang; Kohli, Manu et al. (2005) Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 65:9485-94
Dang, Duyen T; Chen, Xinming; Feng, Jing et al. (2003) Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 22:3424-30
Dang, Duyen T; Zhao, Weidong; Mahatan, Channing S et al. (2002) Opposing effects of Kruppel-like factor 4 (gut-enriched Kruppel-like factor) and Kruppel-like factor 5 (intestinal-enriched Kruppel-like factor) on the promoter of the Kruppel-like factor 4 gene. Nucleic Acids Res 30:2736-41